Viking Therapeutics, Inc. VKTX
29.22 USD +1.64 (+5.95%)
At closeNov 13, 2026, 7:55 PM EST
29.10 -0.12 -0.41%
After hours · Nov 13, 7:55 PM ET
26.69 Day range 29.96
24.21 52-week range 42.13
- YTD
- -16.94%
- 1 year
- -25.08%
News
benzinga.com AMD Sinks 10.5% as Chip Rally Unwinds, Nasdaq 100 Falls 1.7%: Stock Market Today AMD lost about $100 billion as traders unwound the post-Huang chip rotation, Nvidia's China scandal deepened and Cisco slid on margins. QQQ fell 1.7%.
zacks.com 4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead.
fool.com Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028 Viking's oral phase 3 obesity trial is key to expanding its addressable market and securing a favorable market share. Peak sales and valuation projections need to be based on risk-adjusted scenarios.
fool.com Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner? Eli Lilly is one of the undisputed leaders in the weight loss market, and its progress in this area is helping it deliver excellent financial results. However, Viking Therapeutics, a smaller company,…
fxempire.com Viking Therapeutics (VKTX) Price Forecast: Bullish Reversal Targets $43.55 Viking Therapeutics is showing early signs of a bullish reversal, with improving momentum and key support potentially setting up a recovery toward a major consolidation breakout.
zacks.com Novo Up 4% in a Month: How Should Investors Approach the Stock Now? NVO gains 4% in a month on strong Q3 Wegovy pill sales and raised guidance, but intensifying competition and pricing pressures cloud its growth outlook.
prnewswire.com Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026 Poster Presentations Highlight Baseline Characteristics from the Phase 3 VANQUISH-2 Trial of Subcutaneous VK2735 and the Impact of VK2735 on Obesity Severity and Cardiometabolic Parameters in the…
benzinga.com Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $118 Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $106 to $118.
benzinga.com Viking Therapeutics Stock Jumps: What's Going On? Viking Therapeutics Inc (NASDAQ:VKTX) shares are popping Thursday. The obesity drug developer reported third-quarter results that paired a wider-than-expected loss with positive study data and a $960…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Canaccord Genuity Maintains Buy on Viking Therapeutics, Lowers Price Target to $106 Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and lowers the price target from $114 to $106.- benzinga.com UBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94 UBS analyst Joon Lee initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a Buy rating and announces Price Target of $94.
benzinga.com Viking Therapeutics Initiates SUNRISE Phase 3 Clinical Program For Oral VK2735 Dual Agonist Of GLP-1 And Glucose-Dependent Insulinotropic Polypeptide Receptors VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.The SUNRISE Phase 3 program includes two studies…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Truist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85 Truist Securities analyst Joon Lee maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and lowers the price target from $87 to $85.
benzinga.com Viking Therapeutics Begins Exploratory Oral Maintenance Dosing Study Of VK2735, Its Dual Agonist Of Glucagon-Like Peptide 1 And Glucose-Dependent Insulinotropic Polypeptide Receptors VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity. The trial announced today is the second in a two-part…- benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Benzinga Bulls and Bears: Costco, KB Home, McDonald’s Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
benzinga.com S&P 500 Erases Losses as US, Iran Reportedly Discuss Hormuz Deal: Stock Market Today Stocks pared a sharp morning selloff after sources said US and Iranian negotiators are discussing a phased deal to reopen the Strait of Hormuz.
benzinga.com Crude Oil Rises Over 4%; Darden Earnings Miss Views U.S. stocks fell Thursday: Dow -0.7%, S&P 500 -0.46%, Nasdaq -0.7%. Oil jumped 4.4%; Darden missed estimates, while APUS surged 163%.
benzinga.com Why Is Viking Therapeutics Stock Trading Down Thursday? A Viking Therapeutics announcement about an equity and debt offering fuels a reaction in the market.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Profusa (NASDAQ:PFSA) stock increased by 112.5% to $4.36 during Thursday's pre-market session. The company's market cap stands at $1.2 million. GlucoTrack (NASDAQ:GCTK) stock rose 96.55% to…
benzinga.com Stitch Fix Posts Mixed Q4 Results, Joins Viking Therapeutics And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. futures fell as Stitch Fix plunged 18% on weak FY27 guidance; MGM, Viking Therapeutics and other stocks also declined premarket.
benzinga.com Viking Therapeutics Prices Concurrent Public Offerings Of 7,857,143 Shares At $35/Shr And $225M Aggregate Principal Amount Of 2.00% Convertible Senior Notes Due 2032 Viking Therapeutics, Inc. (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of…
benzinga.com Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket GlucoTrack surged 117.7% premarket after Lokahi Therapeutics signed its first external partnership; other stocks saw notable gains and losses.
benzinga.com Viking Therapeutics Stock Drops In After Hours on Proposed Public Offerings Viking Therapeutics shares are moving lower in extended trading Wednesday after the company announced a pair of proposed public offerings.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 90.6% to $3.87 during Wednesday's after-market session. The market value of their outstanding shares is at $1.7 million. Greenland Mines…
benzinga.com QUICK SPARK: Viking Therapeutics Stock Gains 40% in 2 Days Viking Therapeutics stock jumps 40% after VK2735 shows sustained weight loss with less frequent dosing.- benzinga.com Viking Therapeutics Announces $200M Common Stock And $200M Convertible Senior Notes Due 2032; Proceeds To Fund VK2735, VK3019 Clinical Development And General Corporate Purposes Viking Therapeutics, Inc. (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its intention…
- benzinga.com Truist Securities Maintains Buy on Viking Therapeutics, Raises Price Target to $87 Truist Securities analyst Joon Lee maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $83 to $87.
benzinga.com Jaguar Health, IONQ, Viking Therapeutics, Xanadu Quantum and Grab Holdings: Why These 5 Stocks Are on Investors' Radars Today JAGX, IONQ, VKTX, XNDU, GRAB were among the stocks seen trending on Tuesday, Sept. 22, 2026.
benzinga.com Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results U.S. stocks were mixed: Nasdaq and S&P 500 rose while the Dow fell; communication services gained, financials dropped, and Thor Industries climbed 5%.
benzinga.com Nasdaq 100 Flirts with Records, Oil Sinks for Fifth Day: Stock Market Today Nasdaq 100 printed an intraday record on AI enthusiasm while financials slid nearly 2% and crude fell for a fifth straight session.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular session. The company's market cap stands at $1.1 million. Greenland Mines (NASDAQ:GRML) shares moved…
benzinga.com On Holding, Viking Therapeutics, Shopify And Other Big Stocks Moving Higher On Tuesday U.S. stocks rose, led by On Holding's 13% surge after strong guidance and a $1B buyback; Viking Therapeutics and others also gained.
benzinga.com Weight Loss Drug: Viking Therapeutics Says Lead Obesity Drug Shows Weight Retention with Less Frequent Dosing Viking Therapeutics reports positive VK2735 study results showing effective weight maintenance with monthly and biweekly dosing regimens.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Decoy Therapeutics (NASDAQ:DCOY) shares rose 84.0% to $4.71 during Tuesday's pre-market session. The company's market cap stands at $1.6 million. Greenland Mines (NASDAQ:GRML) shares rose…
- benzinga.com Market-Moving News for September 22nd VICR: 13% | Vicor shares are trading higher after the company raised its Q3 revenue guidance. VKTX: 38% | Viking Therapeutics Announces Top-line Results From Maintenance Study Of VK2735, A Dual…
- benzinga.com Viking Therapeutics Announces Top-line Results From Maintenance Study Of VK2735, A Dual Agonist Of GLP-1 And Glucose-Dependent Insulinotropic Polypeptide Receptors; 22% Placebo-Adjusted Weight Loss Reported At Week 33 Following Weekly Dosing Of VK2735At 17.5 MG; No Plateau Observed Results Demonstrate Viability of Monthly and Every Other Week Dosing Regimens for Maintaining Weight Loss; Increasing Options for Adherence to TreatmentUp to 97% of Weight Loss Maintained Following…
- benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com What's Going On With the Dip in Viking Therapeutics Stock? Viking Therapeutics shares are dropping Tuesday amid a risk-off trade, though its longer-term uptrend and sector strength both remain intact.
benzinga.com MongoDB, Credo Technology Group And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session US stock futures lower, MongoDB shares down 13.4% in pre-market trading after earnings beat estimates. Other stocks also declining in pre-market.- benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
- benzinga.com JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65 JP Morgan analyst Hardik Parikh maintains Viking Therapeutics (NASDAQ:VKTX) with a Overweight and lowers the price target from $75 to $65.
benzinga.com Viking Therapeutics Stock Moves Lower: What's Going On? Viking Therapeutics Inc (NASDAQ:VKTX) shares are retreating Thursday despite reporting a narrower second-quarter loss than expected. Here's what you should know.- benzinga.com Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $114 Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $107 to $114.
- benzinga.com Viking Therapeutics Q2 EPS $(1.10) Beats $(1.25) Estimate Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(1.10) per share which beat the analyst consensus estimate of $(1.25) by 12 percent. This is a 89.66 percent decrease over losses of…
- benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Here’s How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 10 Years Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 10 years by 26.85% on an annualized basis producing an average annual return of 40.15%. Currently, Viking Therapeutics has…
benzinga.com Chip Rout Drags Nasdaq 100 Lower, Oil Climbs: Stock Market Today A deepening chipmaker slide pulls all major U.S. indexes lower Tuesday while oil climbs on a Strait of Hormuz strike and defensive sectors led the tape.